Cardiovascular Center and Health Management Center, National Taiwan University Hospital, Yun-Lin Branch, Dou-Liou City, Taiwan 640.
J Clin Endocrinol Metab. 2010 Sep;95(9):4258-67. doi: 10.1210/jc.2010-0332. Epub 2010 Jun 9.
This study assessed the mortality risk associated with metabolic syndrome (MetS) for participants from the Third National Health and Nutrition Examination Survey.
DESIGN, SETTING, AND PATIENTS: The study analyzed mortality data from 1364 men and 1321 women aged 40 yr and older based on their MetS status defined by National Cholesterol Education Program Adult Treatment Panel III. Subjects initially using insulin, oral hypoglycemic, antihypertensive, or lipid-lowering medications were excluded.
All-cause, cardiovascular, cardiac, and noncardiovascular mortality were obtained from the Third National Health and Nutrition Examination Survey-linked mortality follow-up file through December 31, 2000.
The prevalence of MetS was 33 and 29% for men and women, respectively. In the male subjects, there was no significant association between MetS and mortality. In the women, MetS was an independent risk factor for all-cause mortality [hazard ratio (HR) 1.84, 95% confidence interval (CI) 1.29-2.64, P = 0.001], cardiovascular mortality (HR 1.96, 95% CI 1.21-3.17, P = 0.007), cardiac mortality (HR 1.88, 95% CI 1.15-3.09, P = 0.01), and noncardiovascular mortality (HR 1.80, 95% CI 1.13-2.87, P = 0.01). The HR was stronger when postmenopausal women were analyzed separately and became nonsignificant in the premenopausal cohort. The sex-specific HR remained unchanged, regardless of the MetS criteria used or the inclusion of actively treated subjects.
MetS poses a significant increase in mortality risk through an observation period as long as 12 yr, primarily in postmenopausal women, that is not apparent in men and premenopausal women. Sex is an important effect modifier of all-cause and cause-specific death.
本研究评估了代谢综合征(MetS)与第三次全国健康和营养检查调查参与者的死亡率风险的关系。
设计、地点和患者:该研究根据国家胆固醇教育计划成人治疗小组 III 定义的 MetS 状态,分析了 1364 名 40 岁及以上男性和 1321 名女性的死亡率数据。最初使用胰岛素、口服降糖药、降压药或降脂药的患者被排除在外。
所有原因、心血管、心脏和非心血管死亡率均来自第三次全国健康和营养检查调查相关的死亡率随访文件,截止日期为 2000 年 12 月 31 日。
男性和女性的 MetS 患病率分别为 33%和 29%。在男性患者中,MetS 与死亡率之间无显著关联。在女性中,MetS 是所有原因死亡率的独立危险因素[危险比(HR)1.84,95%置信区间(CI)1.29-2.64,P=0.001]、心血管死亡率(HR 1.96,95%CI 1.21-3.17,P=0.007)、心脏死亡率(HR 1.88,95%CI 1.15-3.09,P=0.01)和非心血管死亡率(HR 1.80,95%CI 1.13-2.87,P=0.01)。绝经后女性单独分析时,HR 更强,而绝经前队列中则无统计学意义。无论使用何种 MetS 标准或包括积极治疗的患者,性别特异性 HR 均保持不变。
MetS 在长达 12 年的观察期内显著增加了死亡率风险,主要是在绝经后女性中,而在男性和绝经前女性中并不明显。性别是全因和特定原因死亡的重要效应修饰因子。